Johnson & Johnson (Johnson) It is expected that $2.5 billion of COVID vaccine will be sold this year, despite increasing concerns about the vaccine since its launch.
The company announced the news when it released its second-quarter earnings report early on Wednesday morning.
Johnson & Johnson reported a sales increase of 27.1% in the quarter to US$23.2 billion, a 23% increase in operations during the quarter, and an EPS increase of 72.8% to US$2.35. The company’s revenue was $22.21 billion.
Global sales of COVID vaccines this quarter reached 164 million U.S. dollars.
Pre-market trading of Johnson & Johnson’s shares rose nearly 1%.
The earnings report was released the day after the release of a new, non-peer-reviewed study that showed that the company’s The vaccine does not work well on Delta and Lambda variants As thought before. Researchers in this study recommended booster doses for Johnson & Johnson vaccine vaccinators.
However, Johnson & Johnson released its own data showing that Vaccine is effective against Delta variants, Especially for serious diseases and hospitalization up to eight months after receiving the injection.
Very contagious Delta variant It is sweeping the United States and has been confirmed in 50 states across the country.The US Centers for Disease Control and Prevention said on Tuesday that it is now estimated that there are 83% of new COVID infections In the U.S
Johnson & Johnson’s COVID vaccine has also been Temporarily stop using In April, the U.S. Food and Drug Administration reviewed the link Blood clots in a series of vaccinatorsThe FDA added a warning to the vaccine.
Another warning Guillain-Barré syndrome risk After reporting 100 rare diseases, Johnson & Johnson added them to the Johnson & Johnson vaccine in mid-July.
As of pre-market trading on Wednesday, Johnson & Johnson stock was trading at US$170.00, up US$1.55 or 0.92%.
Photo: Justin Tallis/AFP via Getty Images
